Molecular mechanisms involved in human platelet aggregation by synergistic interaction of platelet-activating factor and 5-hydroxytryptamine
Experimental & Molecular Medicine
; : 226-233, 2001.
Article
de En
| WPRIM
| ID: wpr-144635
Bibliothèque responsable:
WPRO
ABSTRACT
Our recent studies have shown that co-activation of Gq and Gi proteins by 5-hydroxytryptamine (5-HT) and adrenaline show synergism in human platelet aggregation. This study was conducted to examine the mechanism(s) of synergistic interaction of 5-HT and platelet activating factor (PAF) in human platelets. We show that PAF, but not 5-HT, increased platelet aggregation in a concentration-dependent manner. However, low concentrations of 5-HT (2 microM) potentiated platelet aggregation induced by subthreshold concentration of PAF (40 nM) indicating a synergistic interaction between the two agonists and this synergism was blocked by receptor antagonists to either 5-HT or PAF. 5-HT also potentiated the effect of PAF on thromboxane A2 (TXA2) formation and phosphorylation of extracellularly regulated mitogen-activated protein kinases (ERK1/2). The synergism of 5-HT and PAF in platelet aggregation was inhibited by calcium (Ca2+) channel blockers, verapamil and diltiazem, phospholipase C (PLC) inhibitor, U73122, cyclooxygenase (COX) inhibitor, indomethacin, and MEK inhibitor, PD98059. These data suggest that synergistic effect of 5-HT and PAF on human platelet aggregation involves activation of PLC/Ca2+, COX and MAP kinase pathways.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Phosphorylation
/
Pyrrolidones
/
Thromboxane A2
/
Techniques in vitro
/
Cinétique
/
Diltiazem
/
Vérapamil
/
Facteur d'activation plaquettaire
/
Sérotonine
/
Activation plaquettaire
Limites du sujet:
Humans
langue:
En
Texte intégral:
Experimental & Molecular Medicine
Année:
2001
Type:
Article